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ABSTRACT Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an orphan disease and few
data are available on its clinical characteristics. Therefore, we analysed LCNEC registered in the
Netherlands Cancer Registry, and compared data with small cell lung carcinoma (SCLC), squamous cell
carcinoma (SqCC) and adenocarcinoma (AdC).
Histologically confirmed LCNEC (n=952), SCLC (n=11844), SqCC (n=19633) and AdC (n=24253)
cases were selected from the Netherlands Cancer Registry (2003–2012). Patient characteristics, metastasis
at diagnosis (2006 or later), overall survival (OS) including multivariate Cox models and first-line
treatment were compared for stage I–II, III and IV disease.
The number of LCNEC cases increased from 56 patients in 2003 to 143 in 2012, accounting for 0.9% of
all lung cancers. Stage IV LCNEC patients (n=383) commonly had metastasis in the liver (47%), bone (32%)
and brain (23%), resembling SCLC. Median OS (95% CI) of stage I–II, III and IV LCNEC patients was 32.4
(22.0–42.9), 12.6 (10.3–15.0) and 4.0 (3.5–4.6) months, respectively. Multivariate-adjusted OS of LCNEC
patients resembled that of SCLC patients, and was poorer than those of SqCC and AdC patients. However,
frequency of surgical resection and adjuvant chemotherapy resembled SqCC and AdC more than SCLC.
Diagnosis of LCNEC has increased in recent years. The metastatic pattern of LCNEC resembles SCLC as
does the OS. However, early-stage treatment strategies seem more comparable to those of SqCC and AdC.
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Large cell neuroendocrine carcinoma (LCNEC) is a high-grade carcinoma that expresses a neuroendocrine
growth pattern (i.e. organoid, nesting, trabeculae, palisading cells or rosettes) and immunohistochemical
neuroendocrine differentiation. In the third World Health Organization classification (2004), LCNEC was a
subcluster of large cell carcinoma (LCC) and considered as part of the pulmonary neuroendocrine tumor
(NET) spectrum. In the fourth WHO classification (2015), the diagnostic criteria for LCNEC were
reproduced from those proposed in 1999 and LCNEC was moved from the LCC chapter to the NET
chapter [1, 2]. Previous studies have shown that incidence of LCNEC is low, with a reported rate of 3% in
surgically resected case series [3]. Nevertheless, according to the United States Cancer Registry (SEER)
(2003–2007) and the Netherlands Cancer Registry (NCR) (1990–2010), pulmonary LCNEC incidence is
rising [4, 5].
Because LCNEC expresses neuroendocrine features, it is suggested to treat LCNEC as small cell lung
cancer (SCLC) [6, 7]. However, to date, no randomised trials investigating optimal treatment of LCNEC
have been performed. Furthermore, it is unclear whether the LCNEC clinical presentation resembles
non-small cell lung cancer (NSCLC) or SCLC. Recently, in the SEER registry, clinical characteristics of
LCNEC (n=1211), SCLC (n=33304) and LCC (n=8295) were compared. It was shown that compared to
SCLC, LCNEC was more often diagnosed in an early stage and subsequently surgically treated, although
data regarding adjuvant chemotherapy or specific stage III–IV disease treatment were not reported, as
chemotherapy was not registered by SEER.
Series of surgically resected stage I–III lung cancer have shown that LCNEC and SCLC prognosis are
similar [8, 9]. However, the SEER registry concluded that the prognosis of resected early-stage LCNEC
resembled that of LCC and was superior to SCLC [4]. Two small studies in advanced LCNEC (n=25 and
n=14) reported that overall survival (OS) of LCNEC was similar to that of SCLC [10, 11]. In one European
phase II trial, OS of advanced LCNEC patients (n=29) was similar to results found in trials of advanced
SCLC, while the response to chemotherapy was inferior for LCNEC compared to SCLC in a Japanese phase
II trial (n=30) [12, 13].
Thus, from currently available data, it is not clear whether the LCNEC clinical presentation resembles
SCLC or NSCLC. In addition, optimal treatment of LCNEC is not defined by current guidelines. The aim
of this study was to evaluate the clinical presentation, prognosis and currently applied treatment of
LCNEC in comparison to other lung cancer subtypes. Therefore, we analysed data from all histologically
diagnosed LCNEC patients entered in the NCR, and compared those with both SCLC and NSCLC.
Patients and methods
Data sources
For this retrospective population-based study, data for patients diagnosed between 2003 and 2012 were
obtained from the NCR. The registry has a nationwide coverage with >95% completeness of case
ascertainment and patient data are collected in a standardised manner [14]. Furthermore, patients’ records
are linked to the Netherlands Pathology Registry and Centralized Civil Registry for pathology confirmation
and annual vital status update.
Available data were year of diagnosis, histology (based on the International Classifications of Disease–
Oncology (ICD-O), Third Edition), tumour grade, tumour–node–metastasis (TNM) classification (2010 or
later: according to the TNM-7; 2009 or earlier: according to the TNM-6 classification) (generally, as
clinical (c)TNM was overruled by pathological (p)TNM; in cases with neoadjuvant chemotherapy, cTNM
overruled pTNM), first-line treatment modality and time from diagnosis till death or last follow-up.
Metastatic sites at diagnosis (i.e.before treatment) were collected from documented clinical data (cTNM
and/or pTNM) with a maximum of three separate locations. Subsequently, sites of metastases were
combined into organ-specific subcodes (e.g. femur and rib into “bone”).
Study population
NCR data were retrieved on March 21, 2014, and included all patients with a histologically confirmed
diagnosis of LCNEC (ICD-O code 8013), SCLC (8041–8043), SqCC (8050–8084) or AdC (8140–8230,
8250–8550 or 8570–8574), diagnosed between January 1, 2003, and December 31, 2012. AdC cases with
neuroendocrine differentiation (ICD-O-3 code 8574) were clustered into AdC to prevent inclusion of tumours
with neuroendocrine differentiation but without neuroendocrine morphology into the LCNEC cohort.
LCNEC cases classified as grade I–II tumours were not included to avoid possible contamination with
carcinoid tumours. In addition, LCC (not otherwise specified) was omitted as recent evidence suggests that up
to 80% can be classified as SqCC or AdC upon revision in conjunction with immunohistochemical and
molecular profiling [15, 16]. Other exclusion criteria were no recorded TNM classification, metachronous lung
cancer or incomplete survival data.
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To evaluate the clinical characteristics, metastatic pattern, first-line treatment and OS, several subcohorts
were composed: all stages, stage I–II, stage III and stage IV disease. Additionally, first line treatment was
compared separately for patients entered from 2010 to 2012 in order to observe possible temporal and
TNM-6 to TNM-7 transition effects. For metastatic pattern analysis, additional exclusion criteria were
applied: diagnosis before 2006 (since 2006, the metastasis locations were recorded systematically (⩾97%)),
no documentation of metastatic sites, previous malignancy diagnosed within 5 years of lung cancer
diagnoses and patients with stage IV disease classified according to TNM-6 solely based on pulmonary
metastases (possibly T4 in TNM-7, i.e. no stage IV disease). Finally, prevalence of pleural metastasis was
only analysed in patients classified according to TNM-7 to prevent underrating, as TNM-6 recorded
pleural metastasis as IIIB disease and it was not feasible to reclassify this patient group.
This study was approved by the data monitoring committee and the medical ethical board of Maastricht
University Medical Center (Maastricht, The Netherlands). Analyses were performed according to NCR
guidelines and national privacy regulations.
Statistical analysis
Incidence of LCNEC was calculated as fraction of the reported lung cancer incidence [17]. The
Chi-squared and Fisher’s exact test were used to compare categorical data and confidence intervals of
proportions were calculated with the Wald (asymptotic) method. Medians of continuous variables were
compared with a Mann–Whitney U-test. Censoring took place at the closing date (December 31, 2012) or
at the last date of follow-up if patients emigrated. OS was calculated according to the Kaplan–Meier
method and tested with the log-rank test. To examine effects of histology on survival, several stratified
multivariate Cox regression analysis models were constructed including the covariates age, sex, histology,
TNM (7 versus 6), N stage and T stage, and depending on the stage, treatment was included. Assumptions
of proportional hazards were investigated by visual inspection of the complementary log–log plots. In
cases where a hazard ratio (HR) was nonproportional, time-dependent HRs were reported at the cut-off
point where nonproportionality started to influence the results. Two sided p-values <0.05 were considered
significant. Analyses were performed using SPSS (version 22; IBM, Armonk, NY, USA).
TABLE 1 Baseline characteristics according to morphological subtype
Variable Histology p-value versus LCNEC
LCNEC SCLC SqCC AdC SCLC SqCC AdC
Patients n 952 11844 19633 24253
Age years
Mean±SD 65.5±10.5 66.7±9.7 68.8±9.4 64.6±10.7
Median (IQR) 66 (52–80) 67 (53–81) 70 (57–83) 65 (49–81) 0.14# <0.001# <0.001#
Sex 0.01 <0.001 <0.001
Male 595 (62.5) 6903 (58.3) 15055 (76.7) 13404 (55.3)
Female 357 (37.5) 4941 (41.7) 4578 (23.3) 10849 (44.7)
TNM stage <0.001 <0.001 <0.001
I 162 (17.0) 370 (3.1) 4745 (24.2) 5318 (21.9)
II 90 (9.5) 223 (1.9) 2497 (12.7) 1705 (7.0)
III 186 (19.5) 3389 (28.6) 7009 (35.7) 5134 (21.2)
IV 514 (54.0) 7862 (66.4) 5382 (27.4) 12096 (49.9)
Tumour stage <0.001 <0.001 0.002
T1 183 (19.2) 879 (7.4) 2665 (13.6) 5394 (22.2)
T2 297 (31.2) 3234 (27.3) 7886 (40.2) 7903 (32.6)
T3 118 (12.4) 1077 (9.1) 2890 (14.7) 2570 (10.6)
T4 266 (27.9) 4933 (41.6) 5607 (28.6) 6650 (27.4)
Tx 88 (9.2) 1721 (14.6) 585 (2.9) 1736 (7.2)
Nodal stage <0.001 <0.001 0.03
N0 359 (37.7) 2042 (17.2) 8616 (43.9) 10227 (42.2)
N1 96 (10.1) 509 (4.3) 2289 (11.7) 2033 (8.4)
N2 314 (33.0) 6023 (50.9) 6478 (33.0) 7645 (31.5)
N3 183 (19.2) 3270 (27.6) 2250 (11.5) 4348 (17.9)
Data are presented as n (%) unless otherwise stated. LCNEC: large cell neuroendocrine carcinoma; SCLC:
small cell lung carcinoma; SqCC: squamous cell carcinoma; AdC: adenocarcinoma; IQR: interquartile
range; T: tumour; N: node; M: metastasis. #: Mann–Whitney U-test.
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Results
Between 2003 and 2012, 59283 patients with LCNEC, SCLC, SqCC or AdC were entered in the NCR, of
whom 56682 patients were eligible for all-stage analysis (table 1) and 16537 patients for metastatic site
analysis (CONSORT flow diagram in figure 1). 999 (1.7%) out of 59283 histologically selected patients
were diagnosed with LCNEC, of whom 952 were eligible for the study. The total incidence of LCNEC as
proportion of all lung cancers was 0.9%. Annual occurrence of LCNEC increased by 255% from 56 cases
in 2003 to 143 in 2012 (figure 2a and b) with the sharpest increase in 2008. The percentage of LCNEC
diagnosed in stage IV disease increased significantly over time: from 45.0% (n=144) in 2003–2007 to
58.5% (n=370) from 2008 onwards (p<0.001) (figure 2c).
Differences in baseline clinical characteristics
Baseline clinical characteristics are presented in table 1. In LCNEC, 63% were male and the mean±SD age
was 65.5±10.5 years. Compared to LCNEC, the stage distribution of SCLC was more advanced and SqCC
was more frequent diagnosed as early disease. With the exception of a lower percentage of stage I disease,
LCNEC stage distribution was comparable to AdC. Nodal stage (N)2–N3 disease was present in 52% of
Netherlands Cancer Registry
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n=59 283
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FIGURE 1 A CONSORT diagram is presented that describes the selection of cases from the Netherlands Cancer Registry. Patients with
histopathologically diagnosed lung cancer during 2003–2012 were included if diagnosis was according to one of the following morphology codes:
large cell neuroendocrine carcinoma (LCNEC) (8013), small cell lung carcinoma (SCLC) (8041–8043), squamous cell carcinoma (SqCC) (8050–8084)
and adenocarcinoma (AdC) (8140–8230, 8250–8550 or 8570–8574). TNM: tumour–node–metastasis.
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LCNEC, 79% of SCLC (p<0.001), 45% of SqCC (p<0.001) and 49% of AdC (p=0.10). In stage IV patients,
the incidence of N2–N3 disease was significantly lower in LCNEC (69%) than in SCLC (80%) (p<0.001)
and was comparable to SqCC (66%, p=0.30) and AdC (66%, p=0.34).
Prevalence of organ-specific metastasis at diagnosis
LCNEC metastasis occurred in liver (47%), bone (32%), brain (23%), adrenal gland (19%), lung (14%),
pleura (7%) and extrathoracic lymph nodes (16%) (figure 3). LCNEC had significantly fewer liver and
more brain metastasis than SCLC. The prevalence of metastasis was not statistically different in the other
organs. Patients with LCNEC had significantly fewer pleural and lung metastasis but more frequent liver
and extrathoracic lymph node metastasis than patients with SqCC and AdC. Patients with LCNEC had
more brain metastasis than those with SqCC, which was similar in AdC, whereas bone metastasis in
LCNEC occurred less commonly than in patients with AdC.
Comparison of outcome
The median (range) follow-up of the whole cohort was 52 (0–120) months. Median OS (95% CI) of LCNEC
was 8.7 (7.9–9.6), SCLC 7.1 (6.9–7.3), SqCC 13.1 (12.7–13.4) and AdC 11.8 (11.5–12.2) months, respectively
(figure 4). Median OS of stage I–II, III and IV LCNEC was 32.4 (22.0–42.9), 12.6 (10.3–15.0) and 4.0
(3.5–4.6) months, respectively, and that of stage IV chemotherapy-treated LCNEC was 7.7 (6.8–8.6) months.
Table 2 depicts the models used for multivariate analysis of OS. Nonproportionality was observed for the
covariate histology in stage I–II (figure 4b) and, therefore, HRs were calculated separately (i.e. HR for
LCNEC differed between time period of ⩽10 months and >10 months). Patient variable adjusted OS of stage
























































































































































































FIGURE 2 Incidence of histopathologically diagnosed cases of lung cancer registered in the Netherlands Cancer Registry during 2003–2012. a) Trend
in frequency of individual morphological subtypes. b) Trend in frequency of individual morphological subtypes with stage IV. c) Trend in stage
distribution of large cell neuroendocrine carcinoma (LCNEC) between 2003 and 2012. AdC: adenocarcinoma; SqCC: squamous cell carcinoma;

































FIGURE 3 Prevalence of sites of metastases at primary diagnosis of lung cancer recorded between 2006 and 2012. Metastatic sites are clustered
into organ-specific locations and analysed for each lung cancer subtype. All subtypes are compared with large cell neuroendocrine carcinoma
(LCNEC). Error bars represent standard deviations. SCLC: small cell lung carcinoma; SqCC: squamous cell carcinoma; AdC: adenocarcinoma.
#: analysed only in TNM-7. *: p<0.05 by Chi-squared test.
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1.56 (1.21–2.00), respectively). Compared to LCNEC, OS of SqCC and AdC was only significantly better
after 10 months (HR 0.65 (0.52–0.80) and 0.64 (0.52–0.80)). A separate model analysing patients treated
with surgery showed no statistical difference between LCNEC and SCLC, yet the OS of SqCC and AdC
showed similar results to the overall model. In stage III disease, the adjusted model showed no statistically
significant difference between LCNEC and SCLC, SqCC or AdC. In stage IV, the adjusted model revealed
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FIGURE 4 Survival curves for large cell neuroendocrine carcinoma (LCNEC) compared to small cell lung carcinoma (SCLC), squamous cell
carcinoma (SqCC) and adenocarcinoma (AdC) in a) all stages (I–IV), and for stages b) I–II, c) III and d) IV separately. NR: not reached.
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AdC (HR 0.79 (0.72–0.86)). However, in patients treated with chemotherapy, the OS of LCNEC was similar
to that of SCLC while the OS of SqCC and AdC remained significantly longer.
Comparison of first-line treatments
Stage I–II LCNEC was generally treated with surgical resection (87.3%), as was AdC (p=0.09), but fewer
resections were performed in SCLC (p<0.001) and SqCC (p<0.001) (table 3). Adjuvant chemotherapy was
administered to 23.2% of LCNEC patients, which was less than in SCLC (p<0.001) but more frequent
than in SqCC (p<0.001) and AdC (p<0.001). Patients with stage III LCNEC were treated with a
combination of chemotherapy and radiotherapy (30.6%), surgical resection (21.0%), chemotherapy (14.5%)
or received no treatment (19.4%). Treatment practice differed significantly from SCLC (p<0.001) but was
comparable to SqCC (p=0.15) and AdC (p=0.10). In stage IV, 45.7% of LCNEC patients received no
treatment, which was more frequent than in SCLC and AdC (p<0.001), and comparable to SqCC
(p=0.76). Chemotherapy was administered in 38.1% of LCNEC patients. This was significantly less than in
SCLC (p<0.001), more than in SqCC (p<0.001) and was equal to AdC (p=0.65). To explore whether the
time period affected first-line treatment, the time period of 2010–2012 was analysed separately and
compared to 2003–2009 but reported trends remained consistent (data not shown).
Discussion
In this population-based study we confirmed that LCNEC is a rare disease with an average incidence of
0.9% of lung cancer over a 10-year period, while occurrence increased 2.5-fold. The presented results
indicate that LCNEC is a highly aggressive form of lung cancer like SCLC, with a poor prognosis in all
stages of disease. Nevertheless, there were important differences from SCLC: in stage IV, the prognosis of
LCNEC was lower than SCLC, yet similar in selected cases treated with chemotherapy, as well as the
clinical presentation, such as the lower proportion of patients with mediastinal lymph node involvement
and the currently applied treatment in early disease differed from SCLC.
The total incidence of LCNEC (0.9%) as fraction of all diagnosed lung cancer was lower than that reported
by institutional surgical series (1.7–3.0%) [3, 7] but higher than that reported by the population based
SEER registry (0.6%). Probably this is caused by differences in analysed time period (i.e. 2003–2007).
Overall, lung cancer occurrence increased with 24% in the Netherlands (2003–2012), mainly attributed to
the increase in AdC [17]. The increase observed in LCNEC, particularly occurring after 2008, might be
explained by growing awareness among pathologists of this relatively new entity, although at that time, no
new pathology guideline was published. Additionally, an increased use of immunohistochemical
neuroendocrine markers (CD56, synaptophysin and chromogranin-A) in routine diagnostics and an
TABLE 2 Univariate and multivariate analysis of overall survival for large cell neuroendocrine
carcinoma (LCNEC) compared to small cell lung carcinoma (SCLC), squamous cell carcinoma
(SqCC) and adenocarcinoma (AdC)
Stage comparison Variable Histology
LCNEC SCLC SqCC AdC
Stage I–II Unadjusted
<10 months¶ 1 2.16 (1.49–3.15) 1.43 (1.01–2.02) 0.76 (0.54–1.08)
⩾10 months¶ 1 1.62 (1.27–2.08) 0.75 (0.60–0.94) 0.56 (0.45–0.70)
Adjusted+
<10 months¶ 1 1.85 (1.27–2.69) 1.15 (0.82–1.63) 0.84 (0.59–1.19)
⩾10 months¶ 1 1.56 (1.21–2.00) 0.65 (0.52–0.80) 0.64 (0.52–0.80)
Surgical cohort Adjusted§
<10 months¶ 1 0.71 (0.33–1.50) 0.72 (0.49–1.05) 0.56 (0.38–0.82)
⩾10 months¶ 1 1.14 (0.77–1.69) 0.47 (0.37–0.60) 0.52 (0.41–0.66)
Stage III# Unadjusted 1 1.04 (0.88–1.23) 1.00 (0.84–1.18) 0.83 (0.70–0.98)
Adjusted+ 1 0.93 (0.78–1.10) 0.88 (0.74–1.04) 0.86 (0.73–1.02)
Stage IV Unadjusted 1 0.94 (0.86–1.04) 0.88 (0.80–0.97) 0.76 (0.70–0.84)
Adjusted+ 1 0.87 (0.79–0.95) 0.79 (0.72–0.87) 0.79 (0.72–0.86)
Chemotherapy cohort Adjusted+ 1 1.06 (0.91–1.23) 0.85 (0.73–0.99) 0.85 (0.73–0.99)
Data are presented as hazard ratio (95% CI). #: insufficient patients with LCNEC therapeutically treated (e.g. with
chemoradiotherapy or chemotherapy) to allow controlling for treatment; ¶: time stratification used to counter
nonproportionality (occurring for stage I–II); +: for age, sex, tumour–node–metastasis (TNM) edition, T stage and
N stage; §: for age, sex, TNM edition, T stage, N stage and adjuvant chemotherapy.
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increase in core/needle-biopsy sampling in order to obtain sufficient material for molecular testing
(i.e. more tissue) have improved LCNEC diagnosis. In addition, indiscriminate use of markers with low
specificity for neuroendocrine differentiation (i.e. CD56 or NSE) could have increased the diagnostic
frequency on biopsy tissue specimens. Finally, introduction of the IASLC guideline for diagnosis of lung
cancer on biopsies (2011) may have increased awareness of LCNEC diagnosis on biopsies. Currently,
LCNEC on small biopsies is referred to as NSCLC, possibly LCNEC when a neuroendocrine morphology
and neuroendocrine immunohistochemical staining is confirmed in a biopsy specimen [2, 18].
The clinical characteristics of LCNEC corresponded to that of SqCC and AdC closely in the early stage,
whereas LCNEC overlapped with SCLC in metastatic disease. Not only this study but also the SEER
registry reported that the stage distribution of LCNEC resembled NSCLC [4]. A possible explanation is
that advanced LCNEC was underrepresented (e.g. pathologists recognise LCNEC in surgically resected
tissue more easily and may overlook LCNEC when assessing biopsies). However, we also found that
LCNEC patients presented less often with stage N2–N3 compared to SCLC, and this matched SqCC and
AdC, also in stage IV disease. Therefore, it might well be that early-onset LCNEC does not metastasise as
rapidly as SCLC, increasing the chance of diagnosis at an earlier stage, an observation that was recently
also seen in genetically engineered mouse models [18]. Nonetheless, whenever LCNEC has metastasised,
the metastatic pattern resembles SCLC. Unfortunately, the metastatic pattern could not be confirmed in
other studies as numbers of included patients (n=22–86) were too small [3, 7, 19, 20].
Conflicting data are available in the literature with regard to prognosis of LCNEC. The OS of LCNEC in
surgical case series was similar to that of SCLC [8, 9, 21], while the SEER registry showed that OS in very
early (T1N0M0) LCNEC was comparable to LCC and better than SCLC [4]. Resembling the SEER results,
we observed a clear OS difference between LCNEC and SCLC in early-stage disease, but whenever SCLC
was surgically treated, OS resembled LCNEC. The prognostic results in stage IV chemotherapy-treated
patients were in line with two small cohorts that compared OS of LCNEC and SCLC [10, 11] and overall
OS of chemotherapy-treated LCNEC resembled OS of the European phase II trial [12].
TABLE 3 First-line treatment according to morphological subtype
Variable Histology p-value versus LCNEC
LCNEC SCLC SqCC AdC SCLC SqCC AdC
Patients n 952 11844 19633 24253
Treatment in stage I–II <0.01 <0.01 0.441
No treatment 4 (1.6) 68 (11.5) 564 (7.8) 254 (3.6)
Resection 220 (87.3) 114 (19.2) 5039 (69.9) 5816 (82.8)
RT 17 (6.7) 26 (4.4) 1008 (13.9) 601 (8.6)
CT and RT 4 (1.6) 270 (45.5) 288 (4.0) 109 (1.6)
CT 2 (0.8) 94 (15.9) 111 (1.5) 55 (0.8)
Other 5 (2.0) 21 (3.5) 232 (3.2) 188 (2.7)
Stage I–II resections <0.01 <0.01 <0.01
Adjuvant CT 51 (23.2) 91 (75.4) 769 (15.3) 786 (13.5)
Treatment in stage III <0.01 0.15 0.10
No treatment 36 (19.4) 473 (14.0) 1346 (19.2) 801 (15.6)
Resection 39 (21.0) 32 (0.9) 1066 (15.2) 1254 (24.4)
RT 20 (10.8) 55 (1.6) 1120 (16.0) 362 (7.1)
CT and RT 57 (30.6) 1794 (52.9) 2252 (32.1) 1492 (29.1)
CT 27 (14.5) 912 (26.9) 888 (12.7) 879 (17.1)
Other 7 (3.8) 123 (3.6) 337 (4.8) 346 (6.7)
Stage III resections 0.02 0.43 0.75
(Neo)adjuvant CT 21 (53.8) 26 (81.3) 508 (47.7) 707 (56.4)
Treatment in stage IV <0.01 <0.01 <0.01
No treatment 235 (45.7) 2147 (27.3) 2422 (45.0) 4823 (39.9)
Resection 17 (3.3) 7 (0.1) 131 (2.4) 363 (3.0)
RT 30 (5.8) 49 (0.6) 523 (9.7) 435 (3.6)
CT and RT 22 (4.3) 447 (5.7) 325 (6.0) 436 (3.6)
CT 196 (38.1) 4941 (62.8) 1744 (32.4) 4735 (39.1) <0.01 <0.01 0.65
Other# 14 (2.7) 271 (3.4) 237 (4.4) 1304 (10.8)
Data are presented as n (%) unless otherwise stated. LCNEC: large cell neuroendocrine carcinoma;
SCLC: small cell lung carcinoma; SqCC: squamous cell carcinoma; AdC: adenocarcinoma; RT: radiotherapy;
CT: chemotherapy. #: including targeted treatment (e.g. tyrosine kinase inhibitor).
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At present, there are no guidelines that aid physicians in treating LCNEC but we have shown that over
recent years, treatment corresponded to SqCC and AdC more closely than to SCLC. The difference in
(adjuvant) chemotherapy treatment between LCNEC and SCLC in stage I–II and IV was considerable.
Indeed, if LCNEC is considered equally aggressive as SCLC, one would expect the ratio of
chemotherapy-treated patients to be similar. Moreover, in the adjusted multivariate Cox regression
analysis, the prognosis of LCNEC was poorer than that of SCLC. After selection of chemotherapy-treated
patients, the adjusted multivariate Cox regression showed a nonsignificant difference. This increase in
prognosis might be an important sign of possible undertreatment of patients with stage IV LCNEC disease
in the overall population, but requires further investigation.
Because of the rarity of LCNEC, the majority of data comes from single-centre, retrospectively diagnosed
LCNEC series. In this study, for the first time, we describe the clinical manifestation and treatment of both
early- and advanced-disease LCNEC in a large, population-based, histologically diagnosed cohort.
Moreover, we were able to comprehensively define the metastatic pattern of LCNEC at diagnosis and to
compare this with SCLC, SqCC and AdC. By doing this, we excluded possible interference from treatment,
and by excluding patients with previous malignancies, we minimised confounding from other cancers.
The current study has several limitations. Although only histology-selected cases were included, it remains
possible that several tumours diagnosed as LCNEC in this registry were incorrectly classified. In clinical
trials, up to 25–27% of LCNEC diagnosed on biopsies was reclassified into NSCLC or SCLC after central
revision [12, 13]. Furthermore, interobserver studies show poor agreement, underscoring the difficulty in
delineating LCNEC from SCLC and NSCLC [22]. However, this population-based study mirrors daily
practice. A consequence of the histological selection criteria is the observed relatively high fraction of
early-stage NSCLC. Another limitation might be related to the sensitivity of the metastatic pattern analysis
as registration of used modalities for diagnostic imaging was not mandatory. Finally, we were not able to
transcribe TNM-6 into TNM-7, had no data on smoking status, and were not able to adjust for possible
prognostic confounders such as comorbidities, performance score and weight loss, as these variables were
not or insufficiently registered in the NCR.
In summary, LCNEC is increasingly encountered, especially in stage IV disease. We have shown that
LCNEC in clinical practice is a different entity, resembling SqCC and AdC in early-stage disease but with a
comparably poor prognosis and metastatic pattern to SCLC. Nonetheless, possible biological important
differences were present, as LCNEC showed less lymphatic N2–N3 pattern than SCLC. In the near future, it
is expected that the visibility of LCNEC will increase even more for physicians due to the separate mention
of LCNEC in the pulmonary NET chapter of the fourth WHO classification and the recent introduction of
criteria for the diagnosis “NSCLC, possible LCNEC” on biopsy specimens [2, 18]. Therefore, collaboratively
structured international phase III trials are needed to investigate the role of adjuvant chemotherapy in
early-stage disease and optimal disease management of advanced-stage LCNEC. Eventually, this research
can lead to establishment of broadly accepted guidelines for the treatment of LCNEC.
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